Response teams in the Democratic Republic of Congo fighting the Bundibugyo strain of Ebola virus used Anthropic's Claude model to evaluate digitized health worker field reports.

Overview Debates Related claims Topics Sources

Childhood trauma leads people to develop psychosis

Machine-learning antibody profiles differentiated individuals who later developed complicated Crohn's disease from non-complicated Crohn's disease up to approximately 10 years before diagnosis with an AUC value of 0.85.

Machine-learning models integrating early antibody signatures discriminated individuals who would later develop Crohn's disease or ulcerative colitis from healthy controls up to 10 years before diagnosis, with AUC values of 0.90 and 0.84, respectively.

The Percival artificial intelligence model operates in the background to identify health patterns, clinical outcomes, and connections between CT scans, lab values, and physiology without requiring specific direction to search for particular outcomes.

More young people need to get their brain scanned

AstraZeneca and Oracle plan to combine drug development expertise with artificial intelligence and healthcare data to identify eligible patients for clinical trials and monitor safety signals

Satralizumab is a humanized monoclonal antibody designed to bind to soluble and membrane-bound interleukin-6 receptors, inhibiting interleukin-6-mediated inflammatory signaling

Thyroid eye disease is an inflammatory autoimmune condition affecting an estimated 16 women and 3 men per 100,000 population, commonly occurring in people with hyperthyroidism

Satralizumab is the first and only at-home subcutaneous treatment cleared by the FDA for adults with thyroid eye disease

Prior to satralizumab's approval, the FDA approved two intravenous thyroid eye disease treatments targeting the insulin-like growth factor 1 receptor: teprotumumab in 2020 and veligrotug in June 2026

Satralizumab was initially approved by the FDA in 2020 for neuromyelitis optica spectrum disorder, a rare neuroinflammatory condition

Satralizumab can be self-administered subcutaneously by a patient or caregiver following initial training from a healthcare provider

Although satralizumab's SatraGO-1 trial failed to meet its primary efficacy endpoint at week 24, satralizumab received approval based on efficacy results from satralizumab's SatraGO-2

On October 15, 2026, the U.S. Food and Drug Administration approved satralizumab-mwge (Enspryng), developed by Genentech, for adults with thyroid eye disease

The FDA approval of satralizumab for thyroid eye disease was based on data from the global phase 3 SatraGO program, which enrolled 258 patients across 19 countries

In satralizumab's phase 3 SatraGO-2 trial of active thyroid eye disease, 52.9% of satralizumab patients achieved a proptosis response of at least 2 mm reduction (vs. 23.4% placebo) and 60.7% achieved diplopia reduction (vs. 25.8% placebo)

Roche is studying satralizumab in additional neurologic, autoimmune, and inflammatory conditions that may benefit from interleukin-6 signaling inhibition

Thyroid eye disease symptoms can include eye swelling, eyelid retraction, a constant stare, proptosis, diplopia, and pain, which can be disfiguring, debilitating, or blinding

Roche reported that no new safety signals were identified for satralizumab across the phase 3 SatraGO-1 and SatraGO-2 clinical trials

Satralizumab's phase 3 SatraGO trial program demonstrated consistent efficacy in an overall trial population that included patients with both active and chronic thyroid eye disease